Dementia has no cure, which makes prevention one of the few real levers available — and a large trial in rural China just added some of the strongest evidence yet that a genuinely low-tech intervention can move the needle. Bringing blood pressure under tighter control, using local community health workers instead of physicians, reduced dementia risk by 15% over seven years.
Key Takeaways
- The China Rural Hypertension Control Program (CRHCP) followed 33,995 adults over 40 with uncontrolled hypertension across 326 rural villages, half receiving an intensive blood-pressure intervention and half receiving usual care.
- The intervention was delivered by trained non-physician community health workers, not doctors, who adjusted medications using a simple protocol and provided lifestyle coaching, with physician supervision.
- After 7 years, the intervention group had a 15% lower risk of all-cause dementia than the usual-care group, extending findings the same trial first reported after 4 years of follow-up.
- The intervention group also achieved a substantially larger blood pressure reduction (22 mmHg systolic, 9.3 mmHg diastolic more than usual care) and had fewer serious adverse events overall, not more.
How the Trial Was Designed
Led by Professor Yingxian Sun of China Medical University and Professor Jiang He of UT Southwestern Medical Center, the trial randomized 326 villages, evenly split, to either the intervention or usual care. In intervention villages, trained non-physician community healthcare providers — not doctors — initiated and adjusted blood pressure medications using a straightforward, stepped protocol, aiming for a target below 130/80 mmHg, while also coaching participants on lifestyle changes and medication adherence; primary care physicians supervised the program but weren’t the ones managing day-to-day patient care. Usual-care villages continued standard hypertension management through China’s existing rural health insurance system. All participants were 40 or older with uncontrolled hypertension at the study’s start.
What the Results Showed
The trial’s initial results, published in Nature Medicine in April 2025, found that after 4 years, the intervention group’s systolic blood pressure had dropped 22 mmHg more, and diastolic pressure 9.3 mmHg more, than the usual-care group — a substantial gap. That earlier analysis also found a 16% reduction in combined all-cause dementia and mild cognitive impairment, and notably, serious adverse events were less common in the intervention group, not more, addressing a natural worry that more aggressive blood pressure treatment might cause its own problems in older adults.
The new data, presented by Dr. Shanshan Zhong at the European Society of Cardiology Congress in Munich on August 30, extends the follow-up to 7 years and reports a 15% reduction specifically in all-cause dementia — confirming the earlier signal held up, and didn’t fade, with several more years of follow-up. “These results support the long-term sustainability of integrating strategies for blood pressure control… into routine primary care,” Sun said.
Why the Delivery Model Matters as Much as the Result
Professor Sun was direct about the significance of who delivered the intervention: “In this lar